Best Practices and Research Advances in Thoracic Oncology: A Regional Series LATAM Course 1: Liquid Biopsy in Lung Cancer-Liquid Biopsy in Advance Disease

Video Transcription

Video Summary

The webinar discussed predictive biomarkers and surrogate endpoints, focusing on the role of circulating tumor DNA (ctDNA) in non-small cell lung cancer. Post-treatment ctDNA is a powerful prognostic biomarker, yet first-generation assays lack sensitivity, missing about 70% of recurring cases. Newer, more sensitive technologies like phased-sick are improving MRD detection rates. ctDNA offers potential clinical uses, from early detection and screening to monitoring disease progression and acquired resistance to treatments.<br /><br />The discussion highlighted differences between liquid biopsies and traditional tissue biopsies, noting that liquid biopsies are minimally invasive and can effectively capture tumor heterogeneity. Yet, a significant proportion of patients with advanced cancers do not benefit from precision oncology due to inadequate biomarker testing.<br /><br />The value of ctDNA in tracking the evolution of tumors and informing treatment decisions was emphasized. ctDNA dynamics can indicate prognosis and guide therapeutic strategies. Clinical trials are exploring its utility in defining MRD and assessing responses to chemoimmunotherapy. Despite challenges in sensitivity and specificity, ctDNA analysis represents a promising tool for real-time monitoring and treatment adaptation in cancer care, particularly for lung cancer and beyond.

Asset Subtitle

Andres Cardona, MD

Keywords

predictive biomarkers

circulating tumor DNA

non-small cell lung cancer

liquid biopsies

minimal residual disease

precision oncology

chemoimmunotherapy